The firm said it believes that the results of a recent study are representative of the broader utility of the test and its potential for broad application to diagnose concussions.
The financing will go toward the expansion of the company's laboratory operations and acceleration of the sales and marketing efforts of its Syn-One Test.
The firm said its test detects biomarkers inside monocyte blood cells that reflect the reduced clearance of amyloid-beta plaque that leads to Alzheimer's disease.
The researchers at the Royal College of Surgeons Ireland recently received €1.3 million from Wellcome Trust to support the development of the blood-based test.
